FDA Grants Orphan Drug Status To Acceleron's PAH Candidate
Zacks Investment Research | Sep 10, 2019 06:00AM ET
Acceleron Pharma Inc. (NASDAQ:XLRN) announced that the FDA has granted an orphan drug designation to its investigational candidate sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH), a rare disease of highly unmet medical need.
Notably, the orphan drug designation is granted to drugs capable of treating rare diseases that affect less than 200,000 people in the United States. This status also makes the company entitled to certain other benefits including tax credits and grant funding related to clinical study expenses. The tag also makes sotatercept eligible for seven years of marketing exclusivity in the United States upon potential approval from the regulatory body.
Sotatercept is currently being evaluated in two phase II studies for treating PAH. In June, Acceleron completed enrolling patients in the PULSAR study and plans to report top-line data from the same in the first quarter of 2020. Also, the company is currently recruiting subjects in the SPECTRA exploratory study to have a better understanding of sotatercept's potential impact on PAH. Preliminary results from this study are expected in 2020.
Shares of Acceleron were up almost 2.2% following this news on Monday. In fact, so far this year, the stock has gained 4.5% against the industry’s decline of 2.5%.
We would like to remind investors that Acceleron along with global collaboration partner and biotech giant Celgene Corp. (NASDAQ:CELG) is developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia and myelofibrosis.
In June this year, Celgene announced that the FDA accepted its biologics license application (BLA) for luspatercept to treat adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia, who have ring sideroblasts and require red blood cell (RBC) transfusions, and those with beta-thalassemia-associated anemia requiring RBC transfusions.
The FDA has now granted a Priority Review to the BLA for the treatment of beta-thalassemia and also set an action date of Dec 4, 2019. In addition, the regulatory agency has set a target date of Apr 4, 2020 for the evaluation of the MDS indication.
Notably, Acceleron received a $25-million milestone payment from Celgene post the FDA’s acceptance of the BLA for luspatercept. The company is entitled for further milestone fees if the regulatory body approves luspatercept for any of the above-mentioned indications.
Get The News You Want
Zacks Rank & Stocks to Consider
Acceleron currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the healthcare sector include Emmaus Life Sciences, Inc. (NASDAQ:EMMA) and NuCana PLC (NASDAQ:NCNA) , both sporting a Zacks Rank #1 (Strong Buy). You can see .
Emmaus Life’s loss per share estimates have been narrowed 17.8% for 2019 and 26.4% for 2020 over the past 60 days.
NuCana’s loss per share estimates have been narrowed 17.5% for 2019 and 16% for 2020 over the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.